Clinical trials: From bench to bedside to improve outcomes for cancer patients
Clinical trials are crucial to understanding how drugs and therapies work, how safe they are in humans, and how effective they are in treating cancer. They are vital for making...
January 18, 2023
No Comments
Press release: invIOs to present at Biotech Showcase
Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during...
December 14, 2022
No Comments
Three questions to Sarah Bischof, Head of Clinical Operations
1. What are the current main characteristics of clinical trials for cancer treatments? Sarah Bischof: Oncology is a leading area for innovative R&D on many metrics – whether number of...
November 21, 2022
No Comments
Press release: invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a heavily...
November 9, 2022
No Comments
Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…
November 3, 2022
No Comments
Press release: invIOs to present data from clinical stage Cbl-b program at SITC 2022
Vienna, Austria, 18 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401,…
October 18, 2022
No Comments
Press release: invIOs to present at upcoming industry and investor conferences
Vienna, Austria, 11 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival...
October 11, 2022
No Comments
Cancer – the hallmarks and beyond
Although cancer represents a huge challenge for our healthcare systems, new immunotherapies and other advanced novel treatments mean hope is on the horizon. Cancer is one of the all-pervading topics...
September 26, 2022
No Comments
